Lyell Immunopharma (LYEL) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, with voting available online or virtually until June 9, 2026.

• Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.

Voting matters and shareholder proposals

• Election of three Class II directors: Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin, all recommended by the board.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation for named executive officers.

• Proxies may vote on other business arising at the meeting or any adjournments.

Board of directors and corporate governance

• Board recommends all three director nominees for election to Class II positions.